How is ELAHERE (mirvetuximab soravtansine) designed to target and kill cancer cells?
1. ELAHERE attaches to the outside of the cell
2. After binding to FRα, ELAHERE is taken into the cell
3. ELAHERE releases a strong cancer-killing drug inside the cell
4. The cancer-killing drug can also impact other nearby cells that may or may not be cancerous
*Investigator’s choice chemotherapy (ICC)
†MIRASOL study design: A multicentre, open-label, randomised, Phase 3 study evaluating ELAHERE (N=227) vs standard single-agent ICC (paclitaxel, pegylated liposomal doxorubicin or topotecan; N=226). Eligible participants were 18 years of age or older with a confirmed diagnosis of platinum-resistant, high-grade serous ovarian cancer. Participants must have received one to three previous lines of systemic anticancer therapy and had disease progression while receiving or immediately after receiving the previous therapy. Platinum-resistant disease was defined as EOC that recurred within 6 months of the last dose of platinum. FRα-high was defined as ≥75% of viable tumour cells staining with ≥2+ membrane intensity. The primary endpoint was median PFS by investigator assessment (5.62 months for patients treated with ELAHERE vs 3.98 months for patients treated with ICC (HR=0.65 [95% CI: 0.52–0.81]; P<0.0001). Median OS was a key secondary endpoint (16.46 months for patients treated with ELAHERE vs 12.75 months for patients treated with ICC (HR=0.67 [95% CI: 0.50–0.89]; P=0.005).4,5
Abbreviations
ADC, antibody-drug conjugate; CI, confidence interval; EOC, epithelial ovarian cancer; FRα, folate receptor alpha; HR, hazard ratio; ICC, investigator’s choice chemotherapy; mDOR, median duration of response; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SmPC, summary of product characteristics.
References
- Cancer Research UK. Ovarian cancer statistics. Available at: https//www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-bycancer-type/ovarian-cancer [Accessed November 2026]
- Salani R.et al. AM J Obstet Gynecol. 2011:204(6):466-478
- St Laurent J & Liu JF. J Clin Onco. 2024:42(2):127-133
- ELAHERE SmPC
- Moore KN, et al. N Engl J Med. 2023: 389(23):2162-2174
- Eskander RN, et al. Front Oncol. 2023;13:1258228
By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
UK-ELAH-260247. Date of Preparation: November 2026
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com